Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR

Expert Review of Anticancer Therapy

Volumn 12, Issue 12, 2012, Pages 1545-1557

  Felici, Alessandra ^a   Bria, Emilio ^b   Tortora, Giampaolo ^b   Cognetti, Francesco ^a   Milella, Michele ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

metastatic; mTOR inhibitors; renal cell carcinoma; second line treatment; sequential therapy; VEGF receptor tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CABOZANTINIB; DOVITINIB; EVEROLIMUS; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; VASCULOTROPIN INHIBITOR;

CANCER CONTROL; CANCER PROGNOSIS; CANCER RESISTANCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG THERAPY; DRUG TREATMENT FAILURE; HUMAN; HYPERTENSION; KIDNEY METASTASIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEQUENTIAL THERAPY; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84871479033     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.149     Document Type: Review

References (99)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA. Cancer J. Clin. 62(1), 10-29 (2012
2. Linehan WM, Pinto PA, Srinivasan R et al. Identification of the genes for kidney cancer: Opportunity for disease-specific targeted therapeutics. Clin. Cancer Res. 13(2 Pt 2), 671s-679s (2007
3. Linehan WM, Bratslavsky G, Pinto PA et al. Molecular diagnosis and therapy of kidney cancer. Annu. Rev. Med. 61, 329-343 (2010
4. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883-892 2012
5. Xu X, Hou Y, Yin X et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148(5), 886-895 (2012
6. Henske EP. The genetic basis of kidney cancer: Why is tuberous sclerosis complex often overlooked? Curr. Mol. Med. 4(8), 825-831 (2004
7. Maher ER. Von Hippel-Lindau disease. Curr. Mol. Med. 4(8), 833-842 (2004
8. Cook JD, Walker CL. The Eker rat: Establishing a genetic paradigm linking renal cell carcinoma and uterine leiomyoma. Curr. Mol. Med. 4(8), 813-824 (2004
9. Yeung RS. Lessons from the Eker rat model: From cage to bedside. Curr. Mol. Med. 4(8), 799-806 (2004
10. Linehan WM, Pinto PA, Bratslavsky G et al. Hereditary kidney cancer: Unique opportunity for disease-based therapy. Cancer 115(Suppl. 10), 2252-2261 (2009
11. Milella M, Felici A. Biology of metastatic renal cell carcinoma. J. Cancer 2, 369-373 (2011
12. Singer EA, Gupta GN, Srinivasan R. Targeted therapeutic strategies for the management of renal cell carcinoma. Curr. Opin. Oncol. 24(3), 284-290 (2012
13. Posadas EM, Figlin RA. Systemic therapy in renal cell carcinoma: Advancing paradigms. Oncology 26(3), 290-301 (2012
14. Voss MH, Molina AM, Motzer RJ. mTOR inhibitors in advanced renal cell carcinoma. Hematol. Oncol. Clin. North Am. 25(4), 835-852 (2011
15. Escudier B, Albiges L. Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma. Drugs 71(9), 1179-1191 (2011
16. Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: Today and tomorrow. Oncologist 16(Suppl. 2), 45-50 (2011
17. Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: Clinical evidence. Oncologist 16(Suppl. 2), 14-22 (2011
18. Harshman LC, Xie W, Bjarnason GA et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: A populationbased study. Lancet Oncol. 13(9), 927-935 (2012
19. Manola J, Royston P, Elson P et al.; International Kidney Cancer Working Group. Prognostic model for survival in patients with metastatic renal cell carcinoma: Results from the International Kidney Cancer Working Group. Clin. Cancer Res. 17(16), 5443-5450 (2011
20. Powles T, Hutson TE. Difficulty in predicting survival in metastatic renal cancer. Lancet Oncol. 13(9), 859-860 (2012
21. Gore ME, Larkin JM. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br. J. Cancer 104(3), 399-406 (2011
22. Haddad H, Rini BI. Current treatment considerations in metastatic renal cell carcinoma. Curr. Treat. Options Oncol. 13(2), 212-229 (2012
23. Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 16(Suppl. 2), 32-44 (2011
24. Eisen T, Sternberg CN, Robert C et al. Targeted therapies for renal cell carcinoma: Review of adverse event management strategies. J. Natl. Cancer Inst. 104(2), 93-113 (2012
25. Patard JJ, Porta C, Wagstaff J, Gschwend JE. Optimizing treatment for metastatic renal cell carcinoma. Expert Rev. Anticancer Ther. 11(12), 1901-1911 (2011
26. Bellmunt J, Eisen T, Szczylik C, Mulders P, Porta C. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: Establishing customized treatment options. BJU Int. 107(8), 1190-1199 (2011
27. Zustovich F, Lombardi G, Farina P. Treating patients with metastatic renal carcinoma: An escape from Phase III. Expert Rev. Anticancer Ther. 12(7), 919-927 (2012
28. Porta C, Szczylik C, Escudier B. Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: A critical review. Crit. Rev. Oncol. Hematol. 82(3), 323-337 (2012
29. Santos N, Wenger JB, Havre P et al Combination therapy for renal cell cancer: What are possible options? Oncology 81(3-4), 220-229 (2011
30. Escudier B, Negrier S, Gravis G et al Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA Phase II trial. J. Clin. Oncol. 28(Suppl. 15), Abstract 4516 (2010
31. Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer A, Escudier B. Randomized Phase IIIB trial of temsirolimus and bevacizumab versus interferon and bevacizumab in metastatic renal cell carcinoma: Results from INTORACT. Ann. Oncol. Suppl(Proc ESMO), Abstract LBA21 (2012
32. Ravaud A, Barrios CH, Anak O et al. Randomized Phase II study of first-line everolimus (EVE) + bevacizumab (BEV versus interferon alfa-2a (IFN) + BEV in patients (pts) with metastatic renal cell carcinoma (mRCC): RECORD-2. Ann. Oncol. Suppl(Proc. ESMO), Abstract 783 (2012
33. Porta C, Paglino C. Sequencing or not sequencing multikinase inhibitors in kidney cancer: This is the dilemma. Oncol. Rev. 4, 1-3 (2010
34. Sonpavde G, Choueiri TK, Escudier B et al. Sequencing of agents for metastatic renal cell carcinoma: Can we customize therapy? Eur. Urol. 61(2), 307-316 (2012
35. Procopio G, Verzoni E, Iacovelli R, Guadalupi V, Gelsomino F, Buzzoni R. Targeted therapies used sequentially in metastatic renal cell cancer: Overall results from a large experience. Expert Rev. Anticancer Ther. 11(11), 1631-1640 (2011
36. Porta C, Tortora G, Linassier C et al. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: An expert agreement. Med. Oncol. 29(3), 1896-1907 (2012
37. Escudier B, Szczylik C, Porta C, Gore M. Treatment selection in metastatic renal cell carcinoma: Expert consensus. Nat. Rev. Clin. Oncol. 9(6), 327-337 (2012
38. Porta C, Paglino C, Imarisio I. Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: A critical review. Eur. J. Med. Clin. Oncol. 2, 67-72 (2011
39. Calvo E, Ravaud A, Bellmunt J What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFR-TKI? Cancer Treat. Rev. doi:10.1016/j. ctrv.2012.06.010 (2012) (Epub ahead of print
40. Oudard S, Elaidi RT. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: Optimizing patient benefit. Cancer Treat. Rev. 38(8), 981-987 (2012
41. Larriba JL, Espinosa E, Carbonero IG et al. Sequential therapy in metastatic renal cell carcinoma: Pre-clinical and clinical rationale for selecting a second- or subsequent- ine therapy with a different mechanism of action. Cancer Metastasis Rev. 31(Suppl. 1), 11-17 (2012
42. Larkin J, Swanton C, Pickering L. Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Rev. Anticancer Ther. 11(4), 639-649 (2011
43. Park K, Lee JL, Park I et al. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. Med. Oncol. 29(5), 3291-3297 (2012
44. Motzer RJ, Escudier B, Oudard S et al.; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled Phase III trial. Lancet 372(9637), 449-456 (2008
45. Motzer RJ, Escudier B, Oudard S et al.; RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 116(18), 4256-4265 (2010
46. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised Phase 3 trial. Lancet 378(9807), 1931-1939 (2011
47. Motzer RJ, Escudier B, Tomczak P et al. Axitinib vs sorafenib for advanced renal cell carcinoma: Phase III overall survival results and analysis of prognostic factors. Ann. Oncol. Suppl(Proc. ESMO), Abstract 793 (2012
48. Hutson TE, Escudier B, Esteban E et al. Temsirolimus vs sorafenib as second line therapy in metastatic renal cell carcinoma: Results from the INTORSECT trial. Ann. Oncol. Suppl(Proc. ESMO), Abstract LBA22 (2012
49. Rini BI, Michaelson MD, Rosenberg JE et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 26(22), 3743-3748 (2008
50. Bracarda S, Bellmunt J, Melichar B et al. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: A retrospective analysis of the Phase III AVOREN trial. BJU Int. 107(2), 214-219 (2011
51. Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit. Rev. Oncol. Hematol. 77(1), 48-62 (2011
52. Rini BI, Wilding G, Hudes G et al. Phase II study of axitinib in sorafenib- refractory metastatic renal cell carcinoma. J. Clin. Oncol. 27(27), 4462-4468 (2009
53. Sarker D, Molife R, Evans TR et al. A Phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in atients with advanced solid tumors. Clin. Cancer Res. 14(7), 2075-2081 (2008
54. Angevin E, Grunwald V, Ravaud A et al. A Phase II study of Dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J. Clin. Oncol. 29(Suppl.), Abstract 4551 (2011
55. Yakes FM, Chen J, Tan J et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 10(12), 2298-2308 (2011
56. Choueiri TK, Pal SK, McDermott DF et al. Efficacy of Cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). J. Clin. Oncol. 30(Suppl.), Abstract 4504 (2012
57. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A Phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 115(11), 2438-2446 (2009
58. Mackenzie MJ, Rini BI, Elson P et al. Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. Ann. Oncol. 22(1), 145-148 (2011
59. Milella M, Di Lorenzo G, Felici A et al. Medical optimization of Torisel® (motor): A Phase II trial of temsirolimus as second-line treatment for advanced RCC by the Italian Kidney Cancer Group (GIR). Ann. Oncol. Suppl(Proc. ESMO), Abstract 846 (2012
60. Richter S, Pfister SD, Thuer D et al. Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib. Onkologie 31(Suppl.), 234-236 (2008
61. Gerullis H, Bergmann L, Maute L et al. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med. Oncol. 27(2), 373-378 (2010
62. Lamm W, Vogl UM, Bojic M et al. Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma. Acta Oncol. 51(1), 101-106 (2012
63. Heng DY, Mackenzie MJ, Vaishampayan UN et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: Clinical characteristics, risk factors, and subsequent therapy. Ann. Oncol. 23(6), 1549-1555 (2012
64. Albiges L, Iacovelli R, Porta C et al. Prognosis of patients with metastatic renal cell carcinoma (mRCC) with primary resistance to sunitinib - is there any active treatment? Proc. (ECCO/ESMO), Abstract 7143 (2011
65. Elaidi RT, Beuselinck B, Maj-HES A et al. What is the best treatment option for second line in long responders to the first-line TKI in metastatic renal cell carcinoma mRCC) patients (pts): TKI-TKI or TKI-mTORi? A European retrospective study. J. Clin. Oncol. 30(Suppl. 5), Abstract 375 (2012
66. Al-Marrawi MY, Rini BI, Harshman LC et al. The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGFtargeted therapy in metastatic renal cell carcinoma (mRCC) patients (pts). J. Clin. Oncol. 29(Suppl.), Abstract 4555 (2011
67. Iacovelli R, Santoni M, Di Lorenzo G et al. Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (tts) for metastatic renal-cell carcinoma (mRCC). Ann. Oncol. (Suppl. Proc ESMO), Abstract 818 (2012
68. Vickers MM, Choueiri TK, Rogers M et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 76(2), 430-434 (2010
69. Heng DY, Lee JL, Harshman LC et al. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 30(Suppl. 5), Abstract 387 (2012
70. Rini BI. New strategies in kidney cancer: Therapeutic advances through understanding the molecular basis of response and resistance. Clin. Cancer Res. 16(5), 1348-1354 (2010
71. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 10(10), 992-1000 (2009
72. Schor-Bardach R, Alsop DC, Pedrosa I et al Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology 251(3), 731-742 (2009
73. Huang D, Ding Y, Zhou M et al. Interleukin- 8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 70(3), 1063-1071 (2010
74. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8(4), 299-309 (2005
75. Mizukami Y, Jo WS, Duerr EM et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1α-deficient colon cancer cells. Nat. Med. 11(9), 992-997 (2005
76. Fischer C, Jonckx B, Mazzone M et al. Anti-PlGF inhibits growth of VEGFRinhibitor- resistant tumors without affecting healthy vessels. Cell 131(3), 463-475 (2007
77. Fernando NT, Koch M, Rothrock C et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin. Cancer Res. 14(5), 1529-1539 (2008
78. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes Dev. 23(5), 537-548 (2009
79. Marshall S. Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: A nutritional perspective of diabetes, obesity, and cancer. Sci. STKE 2006(346), re7 (2006
80. Herman MA, Kahn BB. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J. Clin. Invest. 116(7), 1767-1775 (2006
81. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell proliferation- AMPK as a therapeutic target for atherosclerosis and cancer. J. Physiol. (Lond.) 574(Pt 1), 63-71 (2006
82. Edinger AL, Thompson CB. An activated mTOR mutant supports growth factorindependent, nutrient-dependent cell survival. Oncogene 23(33), 5654-5663 (2004
83. Di Lorenzo G, Buonerba C, Federico P et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur. Urol. 58(6), 906-911 (2010
84. Di Lorenzo G, Cartenì G, Autorino R et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J. Clin. Oncol. 27(27), 4469-4474 (2009
85. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8(8), 592-603 (2008
86. Pàez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3), 220-231 (2009
87. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 6(9), 734-745 (2007
88. Escudier B, Szczylik C, Hutson TE et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(8), 1280-1289 (2009
89. Motzer RJ, Agarwal N, Beard C et al.; National Comprehensive Cancer Network. Testicular cancer. J. Natl. Compr. Canc. Netw. 10(4), 502-535 (2012
90. Rini BI, Garcia J, Elson P et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J. Urol. 187(5), 1548-1554 (2012
91. Flaherty KT, Robert C, Hersey P et al.; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367(2), 107-114 (2012
92. Chapman PB, Hauschild A, Robert C et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507-2516 (2011
93. Ciuffreda L, Del Bufalo D, Desideri M et al Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901in malignant melanoma with or without BRAF mutations. Neoplasia 11(8), 720-731 (2009
94. Tran HT, Liu Y, Zurita AJ et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: A retrospective analysis of Phase 2 and Phase 3 trials. Lancet Oncol. 13(8), 827-837 (2012
95. Bottos A, Martini M, Di Nicolantonio F et al. Targeting oncogenic serine/threonineprotein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc. Natl Acad. Sci. USA 109(6), E353-E359 (2012
96. McDermott DF. Immunotherapy and targeted therapy combinations in renal cancer. Curr. Clin. Pharmacol. 6(3), 207-213 (2011
97. Bracarda S, Porta C, Boni C et al. Could interferon still play a role in metastatic renal cell carcinoma? a randomized study of two schedules of sorafenib plus interferon-α 2a (RAPSODY). Eur. Urol. (2012) (In Press
98. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012
99. Ribas A. Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 366(26), 2517-2519 (2012)